Cartesian Therapeutics, Inc.
RNAC
Classificação em ações
#18243
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Preço da ação
$6.42
Valor de mercado
$194.24M
Variação (1 dia)
5.59%
Variação (1 ano)
862.09%
País
US
Negociar Cartesian Therapeutics, Inc. (RNAC)
Categoria
Healthcare
Rácio P/B de Cartesian Therapeutics, Inc. (RNAC)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Cartesian Therapeutics, Inc., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Cartesian Therapeutics, Inc. de 2026 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
